tiprankstipranks
Advertisement
Advertisement
Hengrui Subsidiary Wins NMPA Nod for New Indication of Innovative HER2 Breast Cancer Drug
PremiumCompany AnnouncementsHengrui Subsidiary Wins NMPA Nod for New Indication of Innovative HER2 Breast Cancer Drug
25d ago
Hengrui Pharma Wins New China Approval for Hetrombopag Aplastic Anemia Use
Premium
Company Announcements
Hengrui Pharma Wins New China Approval for Hetrombopag Aplastic Anemia Use
1M ago
Jiangsu Hengrui sets March 2026 board meeting to approve 2025 results
Premium
Company Announcements
Jiangsu Hengrui sets March 2026 board meeting to approve 2025 results
1M ago
Hengrui Pharma Signs 20-Year Licensing Deal and Service Pact with Connected Party Hansoh
PremiumCompany AnnouncementsHengrui Pharma Signs 20-Year Licensing Deal and Service Pact with Connected Party Hansoh
4M ago
Jiangsu Hengrui Pharmaceuticals to Hold Extraordinary Shareholders’ Meeting for Key Amendments
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals to Hold Extraordinary Shareholders’ Meeting for Key Amendments
4M ago
Jiangsu Hengrui Pharmaceuticals Proposes Amendments to Articles of Association
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Proposes Amendments to Articles of Association
4M ago
Jiangsu Hengrui Pharmaceuticals to Review Quarterly Results
PremiumCompany AnnouncementsJiangsu Hengrui Pharmaceuticals to Review Quarterly Results
6M ago
Jiangsu Hengrui Pharmaceuticals Licenses Innovative Cancer Drug to Glenmark Specialty
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Licenses Innovative Cancer Drug to Glenmark Specialty
7M ago
Jiangsu Hengrui Pharmaceuticals Approves Resolutions at 2025 Shareholders’ Meeting
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Approves Resolutions at 2025 Shareholders’ Meeting
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100